Odronextamab
| Monoclonal antibody | |
|---|---|
| Type | Bi-specific T-cell engager |
| Source | Humanized |
| Target | CD20, CD3 |
| Clinical data | |
| Other names | REGN1979; REGN-1979 |
| Drug class | Antineoplastic |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Odronextamab (REGN1979) is a CD20 x CD3 bispecific monoclonal antibody that is developed by Regeneron Pharmaceuticals for B-cell non-Hodgkin lymphoma.[1][2][3][4]
Society and culture
Legal status
In June 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Ordspono, intended for the treatment of follicular lymphoma and diffuse large B-cell lymphoma.[5][6] The applicant for this medicinal product is Regeneron Ireland Designated Activity Company.[5]
Names
Odronextamab is the international nonproprietary name.[7]
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Credit:
(see original file).
